Oric Pharmaceuticals (ORIC) Cash & Equivalents (2019 - 2026)

Oric Pharmaceuticals' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $56.4 million for Q1 2026.

• Quarterly Cash & Equivalents rose 14.31% year-over-year to $56.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.4 million (up 14.31% YoY) and the FY2025 annual result came in at $45.7 million, down 23.12% from the prior year.
• Cash & Equivalents was $56.4 million for Q1 2026 at Oric Pharmaceuticals, up from $45.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $112.6 million in Q1 2022 and bottomed at $23.4 million in Q4 2023.
• A 5-year average of $56.3 million and a median of $49.8 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 87.94% — and 2024, when it surged 154.05%.
• Oric Pharmaceuticals' Cash & Equivalents stood at $66.8 million in 2022, then plunged by 65.01% to $23.4 million in 2023, then jumped by 154.05% to $59.4 million in 2024, then declined by 23.12% to $45.7 million in 2025, then advanced by 23.49% to $56.4 million in 2026.
• Business Quant data shows ORIC's Cash & Equivalents at $56.4 million in Q1 2026, $45.7 million in Q4 2025, and $49.7 million in Q3 2025.